PCOS & Hormonal Health

HPG Axis Dysregulation & Ovulation

In PCOS, abnormally elevated GnRH pulse frequency disproportionately drives LH over FSH, sustaining ovarian androgen production and impairing follicular development to the dominant follicle stage required for ovulation. Kisspeptin, as the upstream regulator of GnRH pulsatility, is studied for its potential to normalise this pulsatility pattern. Published clinical trials have documented Kisspeptin's capacity to stimulate LH pulsatility in both hypogonadal and PCOS populations, providing proof-of-concept for HPG axis modulation without direct gonadotropin administration. Gonadorelin, a synthetic GnRH decapeptide, is used clinically in pulsatile pump delivery to restore normal gonadotropin secretion rhythms, with established protocols for ovulation induction in anovulatory PCOS.

Insulin Resistance & Metabolic Correction

Insulin resistance is both a consequence of PCOS hormonal dysregulation and an active driver of androgen excess through its stimulatory effect on ovarian theca cell androgen synthesis. GLP-1 receptor agonists are the most clinically studied pharmacological interventions for PCOS insulin resistance. Tirzepatide's dual receptor agonism produces greater insulin sensitisation than GLP-1 monotherapy, consistent with its superior weight loss outcomes in phase III trials. Semaglutide has been evaluated in small PCOS trials and observational cohorts, with reported improvements in fasting insulin, androgen levels, and menstrual cycle regularity. MOTS-c addresses the mitochondrial dimension of insulin resistance through AMPK activation and metabolic substrate regulation, an upstream mechanism that differs from the receptor-level approach of incretin agonists.

Androgen Reduction via Metabolic Improvement

Elevated insulin drives androgen overproduction in ovarian theca cells via insulin receptor and IGF-1 receptor signalling. By reducing insulin resistance and circulating insulin levels, GLP-1 receptor agonists indirectly lower androgen production through this metabolic pathway. Clinical data from semaglutide and tirzepatide studies in PCOS and obese populations have reported reductions in total testosterone, free androgen index, and DHEAS alongside improvements in insulin sensitivity. This metabolic pathway to androgen reduction is mechanistically distinct from direct anti-androgen pharmacotherapy and may offer advantages in settings where anti-androgens are not tolerated or are contraindicated.

Inflammation & Skin Health

Chronic low-grade inflammation is a consistent feature of PCOS and contributes to both insulin resistance and androgen excess through inflammatory cytokine signalling in adipose and ovarian tissue. Androgenic acne and post-inflammatory hyperpigmentation are among the most clinically visible skin manifestations of PCOS and represent a significant quality-of-life concern for many affected individuals. GHK-Cu, a copper tripeptide with documented anti-inflammatory gene regulation properties, is investigated for skin health through mechanisms that operate at the level of fibroblast activation, collagen synthesis, and cytokine modulation rather than hormonal intervention. Its anti-inflammatory and tissue remodelling effects are relevant to the PCOS skin phenotype independently of its impact on any hormonal parameter.

Sexual Function & Libido

Reduced sexual desire is reported by a substantial proportion of women with PCOS and arises from a combination of hormonal imbalance, body image concerns related to acne and weight, and the psychological burden of a chronic condition affecting fertility and appearance. PT-141 (bremelanotide) acts on MC3R and MC4R receptors in the CNS, activating arousal and desire pathways that are partly independent of circulating androgen or oestrogen levels. This CNS-mediated mechanism makes it relevant in a context where hormonal correction alone, whether via oral contraceptives, anti-androgens, or metabolic improvement, may not fully restore sexual function. PT-141's FDA approval is specific to HSDD in premenopausal women; its use for PCOS-associated sexual dysfunction is investigational and off-label from that indication.

Kisspeptin

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene and produced in hypothalamic KNDy neurons that co-express neurokinin B and dynorphin. These neurons function as the central pulse generator for GnRH release. In PCOS, KNDy neuron activity is dysregulated: elevated GnRH pulse frequency reflects impaired dynorphin-mediated feedback and drives the high LH to FSH ratio characteristic of the condition. Research into exogenous Kisspeptin administration in PCOS is investigating whether normalisation of GnRH pulsatility frequency can restore more physiological gonadotropin secretion. Most published clinical trials have studied Kisspeptin-10 and Kisspeptin-54 in IVF oocyte triggering and hypogonadotropic hypogonadism populations; PCOS-specific pulsatility research is an emerging application. Kisspeptin is not approved for any PCOS indication.

Tirzepatide

Tirzepatide is a synthetic dual agonist at GIP and GLP-1 receptors, distinguishing it from GLP-1 monotherapy compounds. In phase III SURMOUNT trials, Tirzepatide demonstrated 20 to 22 percent mean body weight reduction in obese populations, greater than any approved GLP-1 RA. The GIP receptor agonism component contributes to improved insulin sensitivity through mechanisms complementary to GLP-1 receptor signalling, including enhanced insulin secretion, glucagon suppression, and adipose tissue effects. In the context of PCOS, where insulin resistance is a central pathogenic feature, Tirzepatide's superior insulin sensitisation profile compared to GLP-1 monotherapy represents a research advantage. Emerging trial data from 2024 to 2026 are evaluating Tirzepatide specifically in PCOS populations. It is approved for type 2 diabetes and obesity; PCOS use is off-label.

Semaglutide

Semaglutide is a GLP-1 receptor agonist with an extended half-life enabling once-weekly subcutaneous administration. In STEP trial programmes, semaglutide at 2.4 mg weekly produced approximately 15 to 17 percent mean body weight reduction. Observational studies and small trials in PCOS populations have reported improvements in menstrual cycle regularity, reductions in androgen levels, and improvements in fasting insulin and HOMA-IR in women with PCOS treated with semaglutide, consistent with its insulin-sensitising mechanism. A proportion of women with PCOS who are overweight report restoration of spontaneous ovulation following significant weight loss on GLP-1 RAs, though this outcome depends on multiple individual factors. Semaglutide is approved for type 2 diabetes (Ozempic) and obesity (Wegovy); its use for PCOS is off-label.

Gonadorelin

Gonadorelin is a synthetic decapeptide identical in sequence to endogenous GnRH. When administered in a continuous infusion, it suppresses the pituitary; when delivered in pulsatile fashion via pump at physiological intervals, it restores normal LH and FSH secretion in women with hypothalamic anovulation, including PCOS. Pulsatile Gonadorelin is a well-established fertility treatment for ovulation induction in PCOS, with a clinical evidence base predating GnRH analogue development. It is particularly relevant for women with PCOS who have not responded to clomiphene or letrozole for ovulation induction. Gonadorelin is used in clinical fertility medicine settings under specialist supervision and is not a self-administered research compound in the same category as the other compounds on this page.

PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist with FDA approval (as Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Its mechanism operates through MC3R and MC4R receptors in the hypothalamus and limbic system, activating arousal and desire pathways that are partly independent of circulating sex hormone levels. This is mechanistically relevant in PCOS because sexual dysfunction in this population reflects a combination of hormonal, psychological, and neural factors that may persist even when androgen levels or metabolic parameters improve. PT-141 addresses the CNS component of this dysfunction rather than its hormonal substrate. Its FDA approval is restricted to premenopausal HSDD; PCOS-specific use is investigational. Reported side effects include transient flushing, nausea, and transient blood pressure elevation requiring contraindication screening before use.

GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide whose circulating concentration declines with age. Research has demonstrated its capacity to upregulate genes involved in tissue repair, anti-inflammatory signalling, collagen synthesis, and antioxidant defence. In the context of PCOS, its relevance lies primarily in the skin domain: androgenic acne is among the most prevalent and quality-of-life-impacting skin manifestations of PCOS, and GHK-Cu's anti-inflammatory and fibroblast-activating properties position it as an investigated compound for both active inflammation and post-inflammatory healing. It does not address hormonal drivers of androgen-mediated acne but modulates the tissue-level inflammatory and repair response. GHK-Cu is available topically in cosmetic formulations; subcutaneous administration is used in research protocols.

MOTS-c

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a peptide encoded within mitochondrial DNA and classified as a mitochondria-derived peptide (MDP). It functions as a retrograde mitochondrial signal to the nucleus, activating AMPK and influencing glucose and lipid metabolism pathways in a manner that has been described as exercise-mimetic. In animal models, MOTS-c administration improves insulin sensitivity, reduces adiposity, and protects against diet-induced metabolic dysfunction. Preliminary human data suggest MOTS-c levels decline with age and metabolic disease, consistent with a physiologically relevant role in insulin sensitivity regulation. In PCOS, where mitochondrial dysfunction and impaired AMPK signalling contribute to the metabolic phenotype independently of body weight or adiposity, MOTS-c is investigated as a potential upstream metabolic regulator. It remains investigational; no approved formulation exists.

Clinical observation: restored cycles and unintended pregnancies

Women using semaglutide and liraglutide for PCOS or weight loss have reported restoration of previously absent or irregular menstrual cycles, and a clinically recognised subset have experienced unintended pregnancies. This phenomenon has been documented in case series and retrospective observational data and is now recognised sufficiently that clinicians managing women on these agents routinely address contraception and preconception planning as part of standard care.

The critical caveat: GLP-1 agonists carry pregnancy warnings

The same GLP-1 agonists that can restore ovulation carry FDA and EMA pregnancy warnings based on animal reproductive toxicology data showing embryotoxicity and teratogenicity at clinically relevant doses. Current guidance from both agencies recommends discontinuing GLP-1 agonists at least 2 months before attempting conception. The compound that may enable pregnancy must be stopped before that pregnancy begins. For clinicians managing PCOS patients on GLP-1 agonists who are considering conception, this creates a specific preconception planning obligation: contraception management during treatment, timed discontinuation, and a planned washout window before conception attempts. Full detail on GLP-1 pregnancy risk is covered in the Peptides and Pregnancy reference page.

Regulatory Note

No peptide is currently FDA-approved specifically for PCOS or its individual hormonal features. Tirzepatide and Semaglutide are approved for type 2 diabetes and obesity; their use for PCOS metabolic features is off-label. Gonadorelin is used in clinical fertility medicine for ovulation induction under specialist supervision. PT-141 (Vyleesi) is approved for HSDD in premenopausal women, not specifically for PCOS-associated sexual dysfunction. Kisspeptin and MOTS-c remain investigational compounds without approved formulations in major Western regulatory markets. GHK-Cu is available topically in cosmetic formulations; its research use for PCOS skin concerns is not regulated as a pharmaceutical intervention. This page is an educational research reference and does not constitute medical advice. Any consideration of peptide use in the context of PCOS should involve a qualified clinician familiar with the individual's reproductive, metabolic, and cardiovascular health status.

Which peptides are researched for PCOS?

Several peptide classes have been investigated in PCOS. Kisspeptin and Gonadorelin target HPG axis dysregulation and ovulation. Tirzepatide and Semaglutide address insulin resistance and androgen reduction via GLP-1 receptor agonism. MOTS-c investigates the mitochondrial component of insulin resistance. GHK-Cu is relevant for PCOS-associated skin inflammation and acne. PT-141 addresses PCOS-associated sexual dysfunction through CNS melanocortin pathways. None are approved specifically for PCOS; research in this area is active and evolving.

Can GLP-1 peptides help with PCOS?

GLP-1 receptor agonists are among the most actively investigated compounds for PCOS metabolic features. Observational studies and small trials with Semaglutide have reported improvements in menstrual regularity, reductions in androgen levels, and improvements in insulin sensitivity in women with PCOS. Tirzepatide's superior insulin sensitisation compared to GLP-1 monotherapy is of research interest in PCOS. Neither is approved for PCOS; use in this context is off-label from obesity and type 2 diabetes indications.

What is the role of Kisspeptin in PCOS?

Kisspeptin drives GnRH pulsatility from hypothalamic KNDy neurons. PCOS is characterised by elevated GnRH pulse frequency that preferentially stimulates LH over FSH, supporting androgen production while impairing follicular development and ovulation. Research has investigated whether exogenous Kisspeptin can modulate these pulse patterns to restore more physiological gonadotropin ratios. This application of Kisspeptin in PCOS is an emerging research area; the compound is not approved for this indication.

Do peptides help with PCOS insulin resistance?

Insulin resistance is a primary metabolic target in PCOS. GLP-1 receptor agonists, particularly Tirzepatide and Semaglutide, have the most robust clinical evidence for insulin sensitisation. MOTS-c is investigated as an upstream mitochondrial regulator of insulin sensitivity. Both approaches are investigational or off-label for PCOS specifically. Their use should be considered within the context of a comprehensive PCOS management plan involving a specialist clinician.

Are peptides approved treatments for PCOS?

No peptide is currently FDA-approved specifically for PCOS. Tirzepatide and Semaglutide are approved for type 2 diabetes and obesity; their PCOS use is off-label. Gonadorelin is used in clinical fertility medicine for ovulation induction. PT-141 holds approval for HSDD in premenopausal women. All other compounds on this page are investigational. This page provides research context only and does not constitute medical advice or treatment guidance.

Can GLP-1 agonists help with PCOS-related infertility?

GLP-1 receptor agonists can restore ovulation in some women with PCOS, which in turn enables pregnancy. PCOS-related infertility is primarily driven by insulin resistance and elevated androgens causing anovulation. By improving insulin sensitivity, reducing androgen levels, and promoting weight loss, GLP-1 agonists remove the metabolic obstacle that prevents ovulation. This is not a fertility drug effect in the traditional sense; it is the consequence of correcting an underlying metabolic condition. GLP-1 agonists carry FDA and EMA pregnancy warnings and should be discontinued at least 2 months before attempting conception. See the Peptides and Pregnancy reference page for full detail.

Should I stop semaglutide before trying to get pregnant?

Yes. Current FDA and EMA guidance recommends discontinuing semaglutide at least 2 months before attempting conception, based on pregnancy warnings from animal reproductive toxicology data. For women with PCOS, this creates a specific preconception planning requirement: the drug that may restore ovulation needs to be stopped before actively trying to conceive. Preconception planning with a clinician is essential for anyone with PCOS who is using GLP-1 agonists and considering pregnancy.